Previous 10 | Next 10 |
2023-11-08 16:04:14 ET More on ChromaDex ChromaDex Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on ChromaDex Historical earnings data for ChromaDex Financial information for ChromaDex For further details see: ChromaDex GAAP EPS of ...
Total net sales of $19.5 million, a gross margin of 61.4% and a net loss of $1.0 million while achieving a positive Adjusted EBITDA of $0.5 million and positive operating cash flows for the three months ended September 30, 2023. ChromaDex Corp. (NASDAQ: CDXC) today announced financial r...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Tru Niagen ® Pro 1,000mg is recommended by physicians and used by pro-athletes as it is clinically proven to boost NAD + levels by up to 150% in as little as three weeks ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleoti...
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
ChromaDex Corporation (CDXC) is expected to report $-0.03 for Q3 2023
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, November 8, 2023 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2023...
The global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, ChromaDex, and the #1 selling pet supplement brand in the USA*, Zesty Paws ® , debut cellular health supplement featuring ChromaDex’s industry leading healthy aging ingredient, Nia...
Celebrating a significant achievement in NAD + research, these findings contribute to the mounting evidence indicating that NR may serve as a proactive safeguard against inflammatory cytokines in healthy adults and those with inflammation-related disorders ChromaDex Corp. (N...
This study, which utilized the gold standard method of stable isotopes, reinforces that NMN cannot cross the cell membrane directly and must first be converted to NR ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD + ) research and healthy ...
News, Short Squeeze, Breakout and More Instantly...
ChromaDex Corporation Company Name:
CDXC Stock Symbol:
NASDAQ Market:
ChromaDex Corporation Website:
U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper...
ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen ® supplement, backed by strong financial performance and a robust intellectual property portfolio ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD +...
NR improved the six-minute walking distance and treadmill walking time for those with PAD ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research, shares results from a milestone phase II clinical study showcasing the promising effe...